HSBC Holdings’s Telix Pharmaceuticals TLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$140K Sell
12,730
-3,758
-23% -$42.6K ﹤0.01% 2719
2026
Q2
$190K Buy
+16,488
New +$168K ﹤0.01% 2712

Other funds holding TLX

HSBC Holdings's TLX Position: Q3 2026 in Review

HSBC Holdings reduced its Telix Pharmaceuticals (TLX) stake by 23% in Q3 2026, selling an estimated $42.6K and leaving 12,730 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #2719.

HSBC Holdings first reported a position in TLX in Q2 2026 and has held it in 2 quarters since. The position peaked at $190K in Q2 2026. 74 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

  • HSBC Holdings held 12,730 shares of Telix Pharmaceuticals worth $140K as of Q3 2026.
  • HSBC Holdings sold 3,758 Telix Pharmaceuticals shares in Q3 2026, an estimated $42.6K.
  • Telix Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q3 2026, its #2719 holding.
  • HSBC Holdings first reported a position in Telix Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • HSBC Holdings's Telix Pharmaceuticals position peaked at $190K in Q2 2026.
  • 74 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on HSBC Holdings's 13F filing for Q3 2026, filed 16 Nov 2026.